JP2009527566A5 - - Google Patents

Download PDF

Info

Publication number
JP2009527566A5
JP2009527566A5 JP2008556431A JP2008556431A JP2009527566A5 JP 2009527566 A5 JP2009527566 A5 JP 2009527566A5 JP 2008556431 A JP2008556431 A JP 2008556431A JP 2008556431 A JP2008556431 A JP 2008556431A JP 2009527566 A5 JP2009527566 A5 JP 2009527566A5
Authority
JP
Japan
Prior art keywords
synthetic polymer
composition
polymer
particles
nanoparticle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2008556431A
Other languages
English (en)
Japanese (ja)
Other versions
JP5506196B2 (ja
JP2009527566A (ja
Filing date
Publication date
Priority claimed from US11/707,627 external-priority patent/US8021689B2/en
Application filed filed Critical
Publication of JP2009527566A publication Critical patent/JP2009527566A/ja
Publication of JP2009527566A5 publication Critical patent/JP2009527566A5/ja
Application granted granted Critical
Publication of JP5506196B2 publication Critical patent/JP5506196B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2008556431A 2006-02-21 2007-02-21 免疫治療のためのナノ粒子 Active JP5506196B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US77513206P 2006-02-21 2006-02-21
US60/775,132 2006-02-21
US11/707,627 2007-02-19
US11/707,627 US8021689B2 (en) 2006-02-21 2007-02-19 Nanoparticles for immunotherapy
PCT/US2007/004671 WO2007098254A2 (en) 2006-02-21 2007-02-21 Nanoparticles for immunotherapy

Publications (3)

Publication Number Publication Date
JP2009527566A JP2009527566A (ja) 2009-07-30
JP2009527566A5 true JP2009527566A5 (enExample) 2010-04-08
JP5506196B2 JP5506196B2 (ja) 2014-05-28

Family

ID=38438002

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008556431A Active JP5506196B2 (ja) 2006-02-21 2007-02-21 免疫治療のためのナノ粒子

Country Status (8)

Country Link
US (1) US8021689B2 (enExample)
EP (1) EP1993511B1 (enExample)
JP (1) JP5506196B2 (enExample)
CN (1) CN101437491B (enExample)
AU (1) AU2007217514B2 (enExample)
CA (1) CA2661700C (enExample)
ES (1) ES2709391T3 (enExample)
WO (1) WO2007098254A2 (enExample)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPR011700A0 (en) * 2000-09-14 2000-10-05 Austin Research Institute, The Composition comprising immunogenic virus sized particles (VSP)
WO2007001448A2 (en) * 2004-11-04 2007-01-04 Massachusetts Institute Of Technology Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals
US9267937B2 (en) 2005-12-15 2016-02-23 Massachusetts Institute Of Technology System for screening particles
CA2648099C (en) * 2006-03-31 2012-05-29 The Brigham And Women's Hospital, Inc System for targeted delivery of therapeutic agents
US8367113B2 (en) 2006-05-15 2013-02-05 Massachusetts Institute Of Technology Polymers for functional particles
WO2007137117A2 (en) * 2006-05-17 2007-11-29 Massachusetts Institute Of Technology Aptamer-directed drug delivery
US9381477B2 (en) * 2006-06-23 2016-07-05 Massachusetts Institute Of Technology Microfluidic synthesis of organic nanoparticles
WO2008019142A2 (en) * 2006-08-04 2008-02-14 Massachusetts Institute Of Technology Oligonucleotide systems for targeted intracellular delivery
WO2008147456A2 (en) * 2006-11-20 2008-12-04 Massachusetts Institute Of Technology Drug delivery systems using fc fragments
US9217129B2 (en) 2007-02-09 2015-12-22 Massachusetts Institute Of Technology Oscillating cell culture bioreactor
JP2010523595A (ja) * 2007-04-04 2010-07-15 マサチューセッツ インスティテュート オブ テクノロジー ポリ（アミノ酸）ターゲッティング部分
CA2917512C (en) 2007-10-12 2025-08-05 President And Fellows Of Harvard College VACCINE NANOTECHNOLOGY
US8323696B2 (en) * 2008-08-29 2012-12-04 Ecole Polytechnique Federale De Lausanne Nanoparticles for immunotherapy
US8591905B2 (en) * 2008-10-12 2013-11-26 The Brigham And Women's Hospital, Inc. Nicotine immunonanotherapeutics
US8343498B2 (en) 2008-10-12 2013-01-01 Massachusetts Institute Of Technology Adjuvant incorporation in immunonanotherapeutics
US8277812B2 (en) 2008-10-12 2012-10-02 Massachusetts Institute Of Technology Immunonanotherapeutics that provide IgG humoral response without T-cell antigen
US8343497B2 (en) * 2008-10-12 2013-01-01 The Brigham And Women's Hospital, Inc. Targeting of antigen presenting cells with immunonanotherapeutics
JP5814793B2 (ja) 2008-11-25 2015-11-17 エコール ポリテクニク フェデラル ド ローザンヌ（エーペーエフエル） ブロックコポリマーおよびその使用
US20110223201A1 (en) * 2009-04-21 2011-09-15 Selecta Biosciences, Inc. Immunonanotherapeutics Providing a Th1-Biased Response
WO2010138193A2 (en) 2009-05-27 2010-12-02 Selecta Biosciences, Inc. Targeted synthetic nanocarriers with ph sensitive release of immunomodulatory agents
WO2011150264A2 (en) * 2010-05-26 2011-12-01 Selecta Biosciences, Inc. Synthetic nanocarrier combination vaccines
US9517257B2 (en) 2010-08-10 2016-12-13 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
CN108129554A (zh) 2010-08-10 2018-06-08 洛桑聚合联合学院 红细胞结合性治疗剂
US9850296B2 (en) 2010-08-10 2017-12-26 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
DE102010040565A1 (de) 2010-09-10 2012-03-15 Robert Bosch Gmbh Verfahren zum Einstellen der von einer Feststellbremse ausgeübten Klemmkraft
WO2012061717A1 (en) 2010-11-05 2012-05-10 Selecta Biosciences, Inc. Modified nicotinic compounds and related methods
MX373641B (es) * 2011-04-29 2020-05-04 Selecta Biosciences Inc Nanoportadores sintéticos tolerogénicos para la terapia contra alergias.
CA2843274A1 (en) * 2011-07-29 2013-02-07 Selecta Biosciences, Inc. Synthetic nanocarriers that generate humoral and cytotoxic t lymphocyte (ctl) immune responses
CN104271148A (zh) 2012-02-15 2015-01-07 洛桑聚合联合学院 红细胞结合性治疗剂
WO2013163176A1 (en) 2012-04-23 2013-10-31 Allertein Therapeutics, Llc Nanoparticles for treatment of allergy
US9540428B2 (en) 2012-07-03 2017-01-10 Ecole Polytechnique Federale De Lausanne (Epfl) Extracellular matrix heparin-binding domains
US9879062B2 (en) 2012-07-03 2018-01-30 Ecole Polytechnique Federale De Lausanne Protein-binding peptide isolated from placenta growth factor
KR102233251B1 (ko) 2013-04-03 2021-03-26 엔-폴드 엘엘씨 신규 나노입자 조성물
CN105283175A (zh) * 2013-05-03 2016-01-27 西莱克塔生物科技公司 用于降低的或增强的药效学作用的致耐受性合成纳米载体和治疗性大分子
US10711106B2 (en) 2013-07-25 2020-07-14 The University Of Chicago High aspect ratio nanofibril materials
KR20160102292A (ko) 2014-01-06 2016-08-29 나노코 테크놀로지스 리미티드 표면 변형된 나노입자
US10046056B2 (en) 2014-02-21 2018-08-14 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
US10946079B2 (en) 2014-02-21 2021-03-16 Ecole Polytechnique Federale De Lausanne Glycotargeting therapeutics
US10953101B2 (en) 2014-02-21 2021-03-23 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
SG10202010936RA (en) 2014-02-21 2020-12-30 Ecole Polytecnique Fed De Lausanne Epfl Epfl Tto Glycotargeting therapeutics
US20150359865A1 (en) * 2014-06-17 2015-12-17 Selecta Biosciences, Inc. Tolerogenic synthetic nanocarriers for t-cell-mediated autoimmune disease
KR20170045344A (ko) 2014-09-07 2017-04-26 셀렉타 바이오사이언시즈, 인크. 항-바이러스 전달 벡터 면역 반응을 약화시키기 위한 방법 및 조성물
JP7523909B2 (ja) 2017-03-11 2024-07-29 セレクタ バイオサイエンシーズ インコーポレーテッド 抗炎症剤および免疫抑制剤を含む合成ナノキャリアによる組み合わせ処置に関連する方法および組成物
US20180280488A1 (en) * 2017-03-31 2018-10-04 University of Alaska Anchorage Methods and Compositions for Binding Complement C3 for Targeting of Immune Cells
EP3638296A1 (en) 2017-06-16 2020-04-22 The University Of Chicago Compositions and methods for inducing immune tolerance
WO2019094938A2 (en) 2017-11-13 2019-05-16 The University Of Chicago Methods and compositions for the treatment of wounds
CN112384239A (zh) 2018-05-09 2021-02-19 芝加哥大学 影响免疫耐受的组合物和方法
GB201918963D0 (en) * 2019-12-20 2020-02-05 Provost Fellows Scholars And Other Members Of Board Of Trinity College Dublin Polymeric nanoparticles as vaccine adjuvants
CN114053433B (zh) * 2021-10-20 2024-10-18 北京中医药大学东方医院 刺激响应型纳米材料及其在制备原位肿瘤疫苗中的用途
CN114259463B (zh) * 2022-02-11 2023-03-28 山东大学 一种靶向补体蛋白发挥抗炎作用的PF-HA-diSE水凝胶及其制备方法与应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995003356A1 (en) * 1993-07-23 1995-02-02 Massachusetts Institute Of Technology Nanoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers
US5565215A (en) * 1993-07-23 1996-10-15 Massachusettes Institute Of Technology Biodegradable injectable particles for imaging
GB9406094D0 (en) * 1994-03-28 1994-05-18 Univ Nottingham And University Polymer microspheres and a method of production thereof
JP2000510449A (ja) * 1996-04-10 2000-08-15 南カリフォルニア大学 増殖性硝子体網膜症に対する遺伝子治療
US6083725A (en) * 1996-09-13 2000-07-04 Transkaryotic Therapies, Inc. Tranfected human cells expressing human α-galactosidase A protein
US7157089B1 (en) * 1996-11-26 2007-01-02 Stressgen Biotechnologies Corporation Immune responses using compositions containing stress proteins
GB9718129D0 (en) * 1997-08-27 1997-10-29 Isis Innovation Branched structures
US6333051B1 (en) * 1998-09-03 2001-12-25 Supratek Pharma, Inc. Nanogel networks and biological agent compositions thereof
TWI221854B (en) * 2000-05-26 2004-10-11 Anawrahta Biotech Co Ltd Lac shuttle vectors, kit for expression of a heterologous gene and DNA vaccine carrier containing the same
US6998115B2 (en) * 2000-10-10 2006-02-14 Massachusetts Institute Of Technology Biodegradable poly(β-amino esters) and uses thereof
US7160695B2 (en) * 2001-01-31 2007-01-09 Wyeth Molecules of the PYRIN/NBS/LRR protein family and uses thereof
MXPA03007665A (es) * 2001-02-26 2004-03-16 Univ Duke Polimeros dendriticos novedosos y sus usos biomedicos.
US20040126900A1 (en) * 2001-04-13 2004-07-01 Barry Stephen E High affinity peptide- containing nanoparticles
US7052694B2 (en) * 2002-07-16 2006-05-30 Mayo Foundation For Medical Education And Research Dendritic cell potentiation
US20040247624A1 (en) * 2003-06-05 2004-12-09 Unger Evan Charles Methods of making pharmaceutical formulations for the delivery of drugs having low aqueous solubility
US7846201B2 (en) * 2004-02-20 2010-12-07 The Children's Hospital Of Philadelphia Magnetically-driven biodegradable gene delivery nanoparticles formulated with surface-attached polycationic complex
US7316816B2 (en) * 2004-06-10 2008-01-08 Agency For Science Technology And Research Temperature and pH sensitive copolymers
US20060204443A1 (en) * 2005-03-11 2006-09-14 The Government Of The Usa As Represented By The Secretary Of The Dept. Of Health & Human Services Methods for tumor treatment using dendrimer conjugates

Similar Documents

Publication Publication Date Title
JP2009527566A5 (enExample)
Zhao et al. Advanced bioactive nanomaterials for biomedical applications
Cu et al. Controlled surface modification with poly (ethylene) glycol enhances diffusion of PLGA nanoparticles in human cervical mucus
Chenthamara et al. Therapeutic efficacy of nanoparticles and routes of administration
Moghimi Mechanisms regulating body distribution of nanospheres conditioned with pluronic and tetronic block co-polymers
Faraji et al. Nanoparticles in cellular drug delivery
Drbohlavova et al. Nanocarriers for anticancer drugs-new trends in nanomedicine
Lunov et al. Differential uptake of functionalized polystyrene nanoparticles by human macrophages and a monocytic cell line
Kim et al. Nanomedicine in cancer treatment
Emilian Leucuta Nanotechnology for delivery of drugs and biomedical applications
Urban et al. Nanotools for the delivery of antimicrobial peptides
EP2956119B1 (en) Nanoparticle delivery compositions
Fish et al. Emergence and utility of nonspherical particles in biomedicine
Shen et al. Distribution and Cellular Uptake of PEGylated Polymeric Particles in the Lung Towards Cell-Specific Targeted Delivery: Shen et al.
Kesharwani et al. Cationic bovine serum albumin (CBA) conjugated poly lactic-co-glycolic acid (PLGA) nanoparticles for extended delivery of methotrexate into brain tumors
Thorp et al. Nanoparticle platforms for antigen-specific immune tolerance
JP2015519330A5 (enExample)
Farah et al. Nanocarriers as delivery systems for therapeutics agents
Parmar et al. Factors affecting the clearance and biodistribution of polymeric nanoparticles
Kumeria et al. Enteric polymer-coated porous silicon nanoparticles for site-specific oral delivery of IgA antibody
Kralchevsky et al. Colloid and interface chemistry for nanotechnology
Abdelhamid et al. Nanoparticles advanced drug delivery for cancer cells
Pathak Recent developments in nanoparticulate drug delivery systems
Ganguly et al. Containers for drug delivery
US20240245721A1 (en) Double sided chimeric antigen receptor (car) engineered cell membrane based drug delivery systems